Company / Return on Equity (ROE)
FATE THERAPEUTICS INC Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-58.4%
FY2025
5-year range
-58.4% / -25.5%
FY2021-FY2025
Trend
-33.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
FATE THERAPEUTICS INC reports negative total equity of -58.4% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-58.4% in FY2025 with a 5-year CAGR of -16.9%.
Remained stable around -58.4% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -32.9pp
- 5-Year Change
- -16.9pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 33.8% year-over-year.
- Peak return on equity (roe) was recorded in FY2022.
- Lowest return on equity (roe) in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -58.4% | -33.8% |
| FY2024 | -43.7% | +25.0% |
| FY2023 | -58.2% | -127.9% |
| FY2022 | -25.5% | +36.3% |
| FY2021 | -40.1% | +3.4% |
| FY2020 | -41.5% | +25.4% |
| FY2019 | -55.6% | -21.7% |
| FY2018 | -45.7% | +42.0% |
| FY2017 | -78.8% | +13.7% |
| FY2016 | -91.3% | -122.3% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026